Abstracts tagged "Biologicals"

Abstract Number: 0765 • ACR Convergence 2024
Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
Carmen Lasa Teja¹, Javier Loricera², Diana Prieto-Peña³, fernando lopez gutierrez⁴, Pilar Bernabéu⁵, Mercedes Freire González⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸, Mauricio Mínguez⁹, Beatriz bravo-Mancheño¹⁰, Roser Solans-Laqué¹¹ and Ricardo Blanco-Alonso¹², ¹Hospital Universitario Marqués de Valdecilla, Riotuerto, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁴Rheumatology, madrid, Madrid, Spain, ⁵Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ⁶Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital San Juan de Alicante, Rheumatology., Alicante, Spain, ¹⁰Hospital Universitario Virgen de las Nieves, Granada, Granada., Spain, ¹¹Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ¹²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) seems to be effective in large vessel (LV) vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). LV-GCA phenotype shares some…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 1401 • ACR Convergence 2024
Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Omair Khan¹, Syed Mujtaba Baqir², Azka Naeem², Muhammad Hashim khan², Tharun Shyam², Kseniya Slobodyanyuk³ and Anastasia Slobodnick⁴, ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY, ³Maimonides Medical Center, Manhattan, NY, ⁴Northwell, Staten Island, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
Abstract Number: 1530 • ACR Convergence 2024
Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
Maral DerSarkissian¹, Yan Chen¹, Brendan Rabideau¹, Theo Man¹, Karen Worley², Bernard Rubin³, Karen Costenbader⁴ and S. Sam Lim⁵, ¹Analysis Group, Los Angeles, CA, ²GSK, Collegeville, PA, ³GSK, Durham, NC, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁵Emory University, Atlanta, GA

Background/Purpose: Early diagnosis and treatment of SLE improves prognosis and quality of life.1 Belimumab (BEL), a human immunoglobulin G1λ (IgG1λ) mAb that selectively binds to…
Abstract Number: 1978.5 • ACR Convergence 2024
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Faye Yu¹, Eugene Myshkin², Carolina Bobadilla Mendez³, Marta Cossu⁴, Kaiyin Fei⁵, Qingmin Wang⁶, Matthew J. Loza⁶, Dessislava Dimitrova³ and Sheng Gao³, ¹Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, USA, MA, MA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ⁴Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering IgG…
Abstract Number: 2225 • ACR Convergence 2024
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
Maria Rodriguez-Laguna¹, Leticia Leon², Dalifer Freites Nuñez³, Cristina Hormigos-martin⁴, jose otazu Moudelle⁴, Alfredo Madrid García⁵, Benjamin fernandez-Gutierrez² and lydia Abasolo Alcazar⁶, ¹Resident in Rheumatology, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain, ³Hospital Clínico San Carlos. Madrid. Spain., Madrid, Spain, ⁴Hospital Clínico San Carlos, madrid, Spain, ⁵Fundación para la Investigación Biomédica del Hospital Clínico San Carlos (IDISCC), Madrid, Madrid, Spain, ⁶IdISSC. HCSC, Madrid, Spain
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) who remains symptomatic after failing to multiple therapies are deemed to have "difficult-to-treat" (D2T RA). Fatigue…
Abstract Number: 2431 • ACR Convergence 2024
DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
doria Andrea¹, Ronald Van Vollenhoven², Eric Morand³, Catharina Lindholm⁴, Jonatan Hedberg⁴, Miina Waratani⁵ and Danuta Kielar⁶, ¹University of Padova, Padova, Italy, ²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁵Biopharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁶Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: 2023 EULAR recommendations for the management of SLE open up the option for early treatment initiation with biologics without the requirement to fail immunosuppressants/DMARDs…
Abstract Number: 2652 • ACR Convergence 2024
Characteristics of Relapse and Therapeutic Management in Giant Cell Arteritis in Modern Era, NEWTON Study
Geoffroy Peyrac¹, Natalie Lomba Goncalves¹, Aïcha Kante², Patrice Cacoub³, Karim Sacré⁴, David Saadoun⁵, Thomas Papo⁴, Jean-François Alexandra⁶, Valentin Pagis⁷, Venceslas Bourdin¹, Pascal Richette⁸, Arnaud Vanjak⁹, Augustin Latourte¹⁰, Dikélélé Elessa⁷, William Bigot¹, Ruxandra burlacu⁷, Karine Champion¹, Blanca Amador Borrero⁷, Amanda Lopes¹, Audrey Depond⁷, Peggy Reiner¹¹, Homa Adle-Biassette¹², Aude Couturier¹³, Philippe Bonnin¹⁴, Alexandre Boutigny¹⁵, Frédéric Paycha¹⁶, Anne Couvelard¹⁷, Alexis Régent¹⁸, Benjamin Chaigne¹⁹, Yann Nguyen²⁰, Agnès lefort²⁰, Olivier Bory²¹, Elisabeth Aslangul²², stephane mouly¹, Damien Sène¹, Viet-Thi Tran²³ and Cloé Comarmond¹, and Groupe d'étude français de l'artérite à cellules géantes (GEFA), ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ²Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ³Sorbonne Université, Paris, ⁴Université Paris Cité, Paris, France, ⁵Department of internal medicine, Centre de Référence Maladies Rares autoimmunes et inflammatoires, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France, ⁶INSERM U959, Immunology-Immunopathology-Immunotherapy, Pitié-Salpêtrière Hospital, Paris, France, ⁷Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, ⁸Lariboisière Hospital, Paris, France, ⁹Department of Rheumatoloy, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁰AP-HP, Paris, France, ¹¹Department of Neurology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹²Department of Pathology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹³Department of ophthalmology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁴Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ¹⁵Department of physiology, Lariboisière Hospital, Université Paris Cité, Paris, France, ¹⁶Department of nuclear medicine, Saint-Louis Hospital, Université Paris Cité, Paris, France, ¹⁷Department of Pathology, Bichat Hospital, Université Paris Cité, Paris, Paris, Ile-de-France, France, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France, ²⁰Department of Internal medicine, Beaujon Hospital, Université Paris Cité, Clichy, France, ²¹Department of internal medicine, Louis Mourier Hospital, Université Paris Cité, Colombes, France, ²²Service de Médecine interne, Hôpital Louis Mourier, AP-HP, Colombes, France, ²³Centre for Research in Epidemiology and Statistics (CRESS) and Centre d'Epidémiologie Clinique, Hôtel-Dieu Hospital, Paris, Ile-de-France, France
Background/Purpose: The management of giant cell arteritis (GCA) has evolved with the arrival of tocilizumab (TCZ) and the use of PET/CT. In modern era, a…
Abstract Number: 0292 • ACR Convergence 2024
Liver Disease Complicating Familial Mediterranean Fever: A Study on 57 Patients from the French Adult JIR Cohort
Marion Delplanque¹, xavier amiot², Dominique Wendum³, françois Rodrigues², Rim bourguiba¹, Benoit Terris⁴, Christophe Duvoux², Pierre Bedossa⁵, Didier lebrec⁵, Philippe Sogni², Lucia parlati², Frederic Charlotte², Vlad Ratziu², stephane mouly⁶, jeremy augustin², julien Calderaro², giovana scoazec², JM Vignaud⁷, JA Seyrig⁸, Gilles Grateau¹, Lea Savey⁹ and Sophie Georgin-lavialle¹⁰, ¹Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, Paris, France, ²APHP, Paris, ³APHP, Paris, France, ⁴Department of pathology, Hôpital Cochin, GHU Paris Centre, AP-HP, Université Paris Cité,, Paris, France, ⁵APHP, clichy, ⁶Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁷CHRU nancy, Nancy, ⁸CH centre bretagne, pontivy, ⁹Internal Medicine Department, Tenon Hospital, AP-HP, Paris, France, france, France, ¹⁰Sorbonne Université, Department of internal medicine, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV gene mutations. FMF patients can experience liver involvement, potentially leading…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0587 • ACR Convergence 2024
Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
William Tillett¹, Dafna Gladman², Laure Gossec³, Jason Eells⁴, Patrick Healy⁵, Barbara Ink⁴, Nikos Lyris⁴ and Jessica A Walsh⁶, ¹Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Sorbonne Université, Paris, France, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Morrisville, NC, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) negatively impacts patients’ physical health and functional ability, which can contribute to reduced work productivity.1,2 We examined the association between achieving…
Abstract Number: 0773 • ACR Convergence 2024
Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Leonie Middelink¹, Annemarie Kip², Maarten van der Linden³, Sangeeta Kumari², Stephanie van Dalen², Josephine Stein⁴, Tirza Bruurmijn², Martyn Foster⁵, Peter van Zandvoort², Patrick Round², Eric Meldrum², Helmuth van Es² and Renato Chirivi², ¹Citryll, Oss, Noord-Brabant, Netherlands, ²Citryll BV, Oss, Noord-Brabant, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴Citryll BV, Oss, Noord-Holland, Netherlands, ⁵Experimental Pathology Consultancy, Benfleet, United Kingdom
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of many immune-mediated inflammatory diseases (IMIDs). Though NETosis-targeting therapeutics have shown potential as effective treatments, currently…
Abstract Number: 1056 • ACR Convergence 2024
Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis
Roya Hosseini¹, Lawrence Brown¹, Marc Fleming¹, Rosa Rodriguez-Monguio² and Enrique Seoane-Vazquez¹, ¹Chapman University School of Pharmacy, Irvine, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) treatment has been revolutionized by the development of biologic disease-modifying antirheumatic drugs (bDMARDs), which are increasingly used. The high cost of…
Abstract Number: 1453 • ACR Convergence 2024
Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study
Ling Zhou¹, Juan Zhao¹, Lingyun Sun², Xuan Zhang³, Xiaomei Li⁴, Jiankang Hu⁵, Lijun Wu⁶, Zhenyu Jiang⁷, Min Yang⁸, Xiaoxia Wang⁹, Yongjun Mei¹⁰, Qingchun Huang¹¹, Yongtao Chen¹², Yang Li¹³, Lingli Dong¹⁴, Hui Luo¹⁵, Li Guo¹⁶, Jianguo You¹⁶, Yunpeng Zhang¹⁶, Ke Ren¹⁶ and Huji Xu¹, ¹Shanghai Changzheng Hospital, Shanghai, China (People's Republic), ²Nanjing Drum Tower Hospital, Nanjing, China (People's Republic), ³Beijing Hospital, Beijing, China, ⁴The First Affiliated Hospital of University of Science and Technology of China, Anhui, China (People's Republic), ⁵Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁶People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (People's Republic), ⁷The First Hospital of Jilin University, Changchun, China (People's Republic), ⁸Nanfang Hospital, Guangzhou, China (People's Republic), ⁹Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ¹⁰The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹¹The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ¹²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ¹³Guangdong Provincial People's Hospital, Guangzhou, China (People's Republic), ¹⁴Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹⁵Xiangya Hospital, Central South University, Changsha, China (People's Republic), ¹⁶Kanova Biopharma, Zhejiang, China (People's Republic)
Background/Purpose: XKH004, the first recombinant anti-human IL-17A/F humanized monoclonal antibody in China (also known as XKH004), shares the same therapeutic target as Bimekizumab from UCB…
Abstract Number: 1539 • ACR Convergence 2024
Effectiveness & Safety of Early versus Late Use of Rituximab in Extra-renal Lupus: Real World Experience from a Tertiary Care Centre
JOHN KUMAR DAS¹, ABHILASHA ARVIND MANWATKAR² and JOHN MATHEW², ¹Christian Medical College, Vellore, India, ²christian medical college, vellore, Tamil Nadu, India
Background/Purpose: Rituximab, a monoclonal antibody targeting CD20 positive B cells failed to show effectiveness in SLE, including EXPLORER and LUNAR trials.However, real world data in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].